Advanced Health Intelligence Ltd. announced that the Company will be expanding the current biometric assessment suite with on-mobile device Atrial Fibrillation (AF) service in quarter 2 of 2024 after signing a binding agreement with QOMPIUM NV. AHI is thrilled to be expanding the biometric capabilities the company is bringing to the global healthcare system with the introduction of AF-Scan. This ground-breaking mobile phone-based solution is set to revolutionise the detection and management of Atrial Fibrillation (AF).

This innovative technology is poised to offer unprecedented accessibility and convenience, opening new possibilities in AF monitoring for global populations. With the increasing prevalence of AF and its substantial impact on healthcare systems and economies, AF-Scan will emerge as a critical tool for individuals, healthcare professionals, and public health initiatives. With widespread Approval and Accessibility, Qompium technology has received approval as software as a medical device in multiple countries, including Australia, the European Union (EU), the United Kingdom (UK), the United Arab Emirates (UAE), Saudi Arabia, Singapore, and the United States by the Food and Drug Administration (FDA).

This extensive approval further underscores the reliability and credibility of assisting with AF detection and is a unique and sought-after addition to the AHI biometric assessment offering. Atrial Fibrillation (af) is a prevalent cardiac condition with a substantial impact on public health. AHI's BHA harnesses the power of PPG collected via the flashlight and camera on smartphone to provide downstream services such as AF-Scan with the necessary biometric signals.

The solution is backed by a medically certified AI algorithm that swiftly analyses the PPG measurements it captures. This analysis generates a comprehensive set of graphical data in the form of a report to be consumed by a physician. One can share this report with physician, making discussions about heart health more productive.

AF diagnosis is challenging, often leading to underdiagnosis and misdiagnosis, emphasizing the need for proactive monitoring. AF-Scan is a mobile phone-based solution addressing these challenges. It offers accessibility and convenience, bridging gaps in AF monitoring worldwide.

By empowering individuals to monitor their heartythm, AF-Scan aims to reduce the incidence of complications like strokes and heart failure, optimising healthcare spending. This level of accessibility can potentially transform how approach cardiac health. AI will incorporate the AF-Scan into biometric health assessment platform.

This integration will further enhance the sensor sets already used across multiple disease categories, encompassing a remarkable 41 intrinsic biomarkers. This synergy will provide individuals with a comprehensive health assessment that goes beyond cardiac health, allowing to offer a holistic view of their well-being. AF-Scan offers a game-changing alternative in a market where traditional AF screening and monitoring methods often involve cumbersome processes and visits to healthcare facilities.

By combining the mobile phone with advanced biometric health assessment platform, provide individuals with a powerful tool that empowers them to take control of their health like never before. As the roll out AF-Scan and integrate it into existing platform, are not just launching a product but pioneering a product but pioneering a product.